{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:02:42Z","timestamp":1780020162585,"version":"3.53.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Detecting psilocybin use is challenging because it rapidly converts to its psychoactive metabolite psilocin, and both compounds are unstable in blood. Bufotenin, a structural isomer of psilocin, may exhibit comparable instability in blood. For reliable detection, we developed and validated an LC-MS\/MS method to simultaneously quantify psilocin, bufotenin, and their metabolites, psilocin glucuronide (PSG) and 5-hydroxyindole-3-acetic acid (5-HIAA), in human whole blood. We prepared blood samples by protein precipitation and lipid removal filtration. Analytes were separated using a biphenyl column. The method was validated according to AAFS guidelines with LOQs of 2.4\u2009nM for psilocin, PSG, and bufotenin, and 30\u2009nM for 5-HIAA. We assessed analyte stability in whole blood under conditions relevant to forensic sample handling. Psilocin degraded by 46%\u201366% at room temperature and 66%\u201376% at 4\u00b0C after one day, increasing to 88%\u201399% and 94%\u2013100% after three days. At \u221220\u00b0C, degradation slowed, with up to 51% loss after one month and \u226591% after three months. In contrast, PSG remained stable for 14\u2009days at both room temperature and 4\u00b0C, and for at least one year at \u221220\u00b0C, making it a reliable biomarker of psilocybin intake. Bufotenin showed moderate stability, while 5-HIAA was unsuitable as a biomarker due to its endogenous presence. Our method enables direct quantification of PSG, offering a straightforward and accurate alternative to indirect approaches. We demonstrated the method\u2019s applicability by analyzing 23 forensic blood samples that screened positive for psilocin or PSG, with PSG quantified in nearly all cases, even when psilocin was below LOQ. These findings confirm PSG as a specific and stable biomarker of psilocybin use, and its integration into routine forensic workflows could significantly improve detection reliability.<\/jats:p>","DOI":"10.1093\/jat\/bkag015","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:52:57Z","timestamp":1771505577000},"source":"Crossref","is-referenced-by-count":0,"title":["Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-3906","authenticated-orcid":false,"given":"Marianne Skov-Skov","family":"Bergh","sequence":"first","affiliation":[{"name":"Division of Laboratory Medicine, Department of Forensic Sciences, Oslo University Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2877-0624","authenticated-orcid":false,"given":"Inger Lise","family":"Bogen","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Forensic Sciences, Oslo University Hospital , Oslo,","place":["Norway"]},{"name":"Department of Pharmacy, The Faculty of Mathematics and Natural Sciences, University of Oslo , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9717-9913","authenticated-orcid":false,"given":"Merete","family":"Vevelstad","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Forensic Sciences, Oslo University Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-5863","authenticated-orcid":false,"given":"\u00c5se Marit Leere","family":"\u00d8iestad","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Forensic Sciences, Oslo University Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"2026052821164943600_bkag015-B1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/0269881121992676","article-title":"Dose-response relationships of psilocybin-induced subjective experiences in humans","volume":"35","author":"Hirschfeld","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2026052821164943600_bkag015-B2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026052821164943600_bkag015-B3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40262-024-01454-4","article-title":"Clinical pharmacokinetics of psilocin after psilocybin administration: a systematic review and post-hoc analysis","volume":"64","author":"Otto","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026052821164943600_bkag015-B4","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","article-title":"Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2026052821164943600_bkag015-B5","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.3390\/ijms21239279","article-title":"Toxicology and analysis of psychoactive tryptamines","volume":"21","author":"Malaca","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026052821164943600_bkag015-B6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/00365510510013604","article-title":"Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues","volume":"65","author":"K\u00e4rkk\u00e4inen","year":"2005","journal-title":"Scand J Clin Lab Invest"},{"key":"2026052821164943600_bkag015-B7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00414-012-0796-1","article-title":"Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS\/MS","volume":"127","author":"Martin","year":"2013","journal-title":"Int J Legal Med"},{"key":"2026052821164943600_bkag015-B8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/02791072.1996.10472488","article-title":"Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic","volume":"28","author":"Lyttle","year":"1996","journal-title":"J Psychoactive Drugs"},{"key":"2026052821164943600_bkag015-B9","doi-asserted-by":"publisher","first-page":"1032638","DOI":"10.1155\/2018\/1032638","article-title":"Biological effects and biodistribution of bufotenine on mice","volume":"2018","author":"Vigerelli","year":"2018","journal-title":"Biomed Res Int"},{"key":"2026052821164943600_bkag015-B10","author":"The Lovdata Foundation"},{"key":"2026052821164943600_bkag015-B11","author":"Government of the United Kingdom"},{"key":"2026052821164943600_bkag015-B12","author":"United States Drug Enforcement Administration"},{"key":"2026052821164943600_bkag015-B13","author":"European Union Drugs Agency","year":"2025"},{"key":"2026052821164943600_bkag015-B14","author":"The National Criminal Investigation Service"},{"key":"2026052821164943600_bkag015-B15","doi-asserted-by":"publisher","first-page":"111086","DOI":"10.1016\/j.drugalcdep.2024.111086","article-title":"National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017\u20132022","volume":"258","author":"Palamar","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"2026052821164943600_bkag015-B16","doi-asserted-by":"publisher","first-page":"122486","DOI":"10.1016\/j.jchromb.2020.122486","article-title":"Development and validation of an LC-MS\/MS method for the bioanalysis of psilocybin\u2019s main metabolites, psilocin and 4-hydroxyindole-3-acetic acid, in human plasma","volume":"1164","author":"Kolaczynska","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026052821164943600_bkag015-B17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/1556-4029.15454","article-title":"Quantification of psilocin in human whole blood using liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS)","volume":"69","author":"Gomonit","year":"2024","journal-title":"J Forensic Sci"},{"key":"2026052821164943600_bkag015-B18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1355-0306(06)71579-9","article-title":"Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography","volume":"46","author":"Anastos","year":"2006","journal-title":"Sci Justice"},{"key":"2026052821164943600_bkag015-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.01.006","article-title":"Synthesis, hydrolysis and stability of psilocin glucuronide","volume":"237","author":"Martin","year":"2014","journal-title":"Forensic Sci Int"},{"key":"2026052821164943600_bkag015-B20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0378-4347(98)00067-X","article-title":"Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid\u2013liquid extraction with automated on-line solid-phase extraction","volume":"709","author":"Lindenblatt","year":"1998","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"2026052821164943600_bkag015-B21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00414-011-0652-8","article-title":"A validated method for quantitation of psilocin in plasma by LC\u2013MS\/MS and study of stability","volume":"126","author":"Martin","year":"2012","journal-title":"Int J Legal Med"},{"key":"2026052821164943600_bkag015-B22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of escalating doses of oral psilocybin in healthy adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2026052821164943600_bkag015-B23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s0031-6865(97)00014-9","article-title":"Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man","volume":"72","author":"Hasler","year":"1997","journal-title":"Pharm Acta Helv"},{"key":"2026052821164943600_bkag015-B24","doi-asserted-by":"publisher","first-page":"1391689","DOI":"10.3389\/fphar.2024.1391689","article-title":"In vitro and in vivo metabolism of psilocybin\u2019s active metabolite psilocin","volume":"15","author":"Thomann","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026052821164943600_bkag015-B25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0379-0738(00)00213-9","article-title":"Detection of psilocin in body fluids","volume":"113","author":"Sticht","year":"2000","journal-title":"Forensic Sci Int"},{"key":"2026052821164943600_bkag015-B26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.109.031138","article-title":"Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucurono\u00adsyltransferases","volume":"38","author":"Manevski","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2026052821164943600_bkag015-B27","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/0024-3205(76)90441-0","article-title":"Metabolism of bufotenine-2\u2032-14C in human volunteers","volume":"19","author":"Sanders-Bush","year":"1976","journal-title":"Life Sci"},{"key":"2026052821164943600_bkag015-B28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0165-1781(95)02747-K","article-title":"Urinary \u00adexcretion of bufotenin (N, N-dimethyl-5-hydroxytryptamine) is increased in suspicious violent offenders: a confirmatory study","volume":"58","author":"K\u00e4rkk\u00e4inen","year":"1995","journal-title":"Psychiatry Res"},{"key":"2026052821164943600_bkag015-B29","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0004563214554842","article-title":"Transient elevation of serum 5-HIAA by dietary serotonin and distribution of 5-HIAA in serum protein fractions","volume":"52","author":"Tohmola","year":"2015","journal-title":"Ann Clin Biochem"},{"key":"2026052821164943600_bkag015-B30","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.fsir.2023.100336","article-title":"Legal limits for driving under the influence of illicit drugs: large variations between jurisdictions","volume":"8","author":"Gjerde","year":"2023","journal-title":"Forensic Sci Int Rep"},{"key":"2026052821164943600_bkag015-B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11419-006-0006-2","article-title":"Direct detection of serum psilocin glucuronide by LC\/MS and LC\/MS\/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a \u201cmagic mushroom\u201d user","volume":"24","author":"Kamata","year":"2006","journal-title":"Forensic Toxicol"},{"key":"2026052821164943600_bkag015-B32","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2026052821164943600_bkag015-B33","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacol"},{"key":"2026052821164943600_bkag015-B34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0731-7085(02)00278-9","article-title":"Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man","volume":"30","author":"Hasler","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"2026052821164943600_bkag015-B35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jchromb.2003.08.030","article-title":"Optimized glucuronide hydrolysis for the detection of psilocin in human urine samples","volume":"796","author":"Kamata","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026052821164943600_bkag015-B36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsycho\u00adpharmacology"},{"key":"2026052821164943600_bkag015-B37","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.talo.2022.100171","article-title":"Determination of tryptamine analogs in whole blood by 96-well electromembrane extraction and UHPLC-MS\/MS","volume":"7","author":"Sch\u00fcller","year":"2023","journal-title":"Talanta Open"},{"key":"2026052821164943600_bkag015-B38","author":"American Academy of Forensic Sciences (AAFS)"},{"key":"2026052821164943600_bkag015-B39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jat\/bkab075","article-title":"A single method for 127 recommended and additional DUID drugs in blood and urine by LC\u2013MS-MS","volume":"46","author":"Farley","year":"2022","journal-title":"J Anal Toxicol"},{"key":"2026052821164943600_bkag015-B40","first-page":"117","article-title":"urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia","volume":"31","author":"Emanuele","year":"2010","journal-title":"Neuro Endocrinol Lett"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkag015\/67065382\/bkag015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/4\/bkag015\/67065382\/bkag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/4\/bkag015\/67065382\/bkag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:16:52Z","timestamp":1780017412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/doi\/10.1093\/jat\/bkag015\/8494532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkag015","relation":{},"ISSN":["1945-2403"],"issn-type":[{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,22]]},"article-number":"bkag015"}}